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Abstract
Background: Little is known about how pediatricians or internists manage influenza symptoms.
Recent guidelines on antiviral prescribing by the Centers for Disease Control and Prevention
(CDC) make almost no distinction between adults and children. Our objective was to describe how
pediatricians in two large academic medical institutions manage influenza and compare them to
internists.
Methods: At the end of the 2003–4 influenza season, we conducted a cross sectional on-line
survey of physician knowledge, attitudes and practices regarding rapid diagnostic testing and use of
antiviral therapy for influenza at two large academic medical centers, one in Massachusetts and the
other in Texas. We collected data on self-reported demographics, test use, prescribing practices,
and beliefs about influenza and anti-influenza drugs.
Results: A total of 107 pediatricians and 103 internists completed the survey (response rate of
53%). Compared to internists, pediatricians were more likely to perform rapid testing (74% vs.
47%, p < 0.0001), to use amantadine (88% vs. 48%, p < 0.0001), to restrict their prescribing to high-
risk patients (86% vs. 53%, p < 0.0001), and to believe that antiviral therapy could decrease
mortality (38% vs. 22%, p = 0.01). Other beliefs about antiviral therapy did not differ statistically
between the specialties. Internists were more likely to be unfamiliar with rapid testing or not to
have it available.
Conclusion: Pediatricians and internists manage influenza differently. Evidence-based guidelines
addressing the specific concerns of each group would be helpful.
Background
Influenza occurs in winter epidemics, affecting 5–20% of
the population each year [1]. Children account for the
majority of cases, but most of the morbidity and mortality
occurs in elderly and other high-risk adults. Diagnosis can
be made on clinical grounds [2-4] or by the use of rapid
tests, which are widely available [5]. If diagnosed within
48 hours, 4 antiviral medications can be used to shorten
the course of illness and prevent secondary infections
requiring antibiotics [6]. There are no comparative trials,
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and most of the studies include only healthy adults; there
are few studies of children [7-12]. Even less is known
about high-risk patients. Based on the available data, the
efficacy in children and adults appears similar, though
high-risk adults may benefit more than either group [13].
Guidelines issued by the Centers for Disease Control and
Prevention (CDC) in 2006 [14] do not distinguish
between adults and children in their recommendations,
except to point out that oseltamivir is licensed only for
children aged ≥ 1 year and zanamivir for children aged ≥
7 years. There are also no specific recommendations on
whom to test.
The influenza epidemic of 2003–2004 was marked by its
severity and the large number of pediatric deaths, which
garnered significant media attention [15]. In the absence
of official treatment guidelines, we hypothesized that
pediatricians and internists would manage influenza dif-
ferently, because complication rates and medication side
effects differ between pediatric and adult populations.
Methods
Setting
Baystate Health, comprised of a 650-bed tertiary care
center, 3 affiliated neighborhood health centers and a
330-physician multispecialty practice, provides primary
and tertiary care to residents of Western Massachusetts.
Baystate also serves as the western campus of the Tufts
University School of Medicine. Scott & White Hospital
and Clinic is located in Temple, Texas. It is comprised of a
550-physician multi-specialty group practice, a 503-bed
tertiary care hospital and a self-contained Health Plan.
Scott and White serves as the primary teaching hospital for
the Texas A&M University College of Medicine.
Study Design
We conducted a cross-sectional study of physician knowl-
edge, attitudes and practices surrounding rapid diagnosis
and antiviral therapy for influenza. The methodology has
already been described [16]; this report focuses on differ-
ences between pediatricians and internists. During March
and April of 2004 we sent direct e-mail invitations to
members of the departments of pediatrics (n = 101) and
medicine (n = 148) at Baystate Medical Center and the
departments of pediatrics (n = 49) and medicine (n = 97)
at Scott and White Hospital, inviting them to participate
in an on-line influenza survey. Subjects were excluded if
they did not have a valid e-mail address or did not care for
patients with influenza.
Data were collected using a self-administered 41-question
web-based survey (see Additional file 1), devised by the
investigators. The survey contained questions about
demographics (specialty, degree, years-in-practice and
practice size), antiviral prescribing (numbers of prescrip-
tions of various drugs, target groups and reasons for not
prescribing), rapid testing (use of the test, choice of test
and reasons for not testing) and influenza beliefs. We sent
an initial e-mail explaining that the purpose of the survey
was to study their knowledge, attitudes and practices
regarding influenza testing and treatment. Anonymity was
assured and completion of the survey implied informed
consent. The study was approved by the institutional
review board at each hospital. The survey ended on June
15, 2004.
Statistical Analysis
The data were entered automatically into an electronic
database by the internet survey company (surveymon-
key.com), then downloaded into SAS version 9.1.3 (SAS
Institute, Inc., Cary, NC). Responses were compared using
the Chi-square or Fisher's exact tests, as appropriate. We
created logistic regression models of each of the main
study outcomes (prescribing antiviral therapy, prescribing
amantadine, performing rapid testing and only treating
high risk patients) controlling for specialty, location,
patient volume, physician beliefs, and performance of
rapid testing (for treatment outcomes only) using back-
ward variable selection technique. P-values of less than
0.05 were considered statistically significant.
Results
A total of 210 physicians in the two surveyed institutions
completed the survey; 107 pediatricians and 103
internists (response rate of 54% for pediatricians and 52%
for internists). Pediatricians reported that they were more
likely to perform rapid testing than internists (73% vs.
46%, p < 0.0001), and more likely to treat with antiviral
drugs, though the association did not reach statistical sig-
nificance (Table 1). Pediatricians reported that they were
also more likely than internists to use amantadine (88%
vs. 48%, p < 0.0001), but not oseltamivir, and to restrict
their prescribing to high-risk patients (86% vs. 53%, p <
0.0001). Differences in beliefs about the ability of antivi-
ral therapy to shorten the course of illness and to prevent
complications requiring antibiotics were not statistically
significant, but more pediatricians than internists
reported that they believed antiviral therapy could
decrease mortality (38% vs. 22%, p = 0.01).
Reasons for not performing rapid testing and for not pre-
scribing antiviral therapy are shown in Figures 1 and 2,
respectively. Fewer pediatricians than internists reported
that they were unfamiliar with rapid tests (14% vs. 43%,
p = 0.009) or that the tests were not available (14% vs.
42%, p = 0.013). There was no statistical difference
between specialties in their reasons for not prescribing
antivirals. The most common reason reported was
patients presented too late. Interestingly, no physician
cited antiviral resistance as a reason for not prescribing.BMC Pediatrics 2008, 8:15 http://www.biomedcentral.com/1471-2431/8/15
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In multivariate analysis, specialty remained significant for
amantadine prescribing, rapid testing and restricting pre-
scribing to high risk patients, but was not associated with
antiviral prescribing overall (Table 2). Location, patient
volume and the belief that antiviral therapy can decrease
mortality were all associated with antiviral prescribing,
but not with performance of rapid testing or restricting
antiviral prescribing to high risk patients.
Discussion
Our hypothesis that pediatricians and internists would
differ in their management of influenza was borne out by
the data. More pediatricians than internists were familiar
with and performed rapid testing, perhaps because pedia-
tricians are familiar with office-based rapid testing for res-
piratory syncytial virus and streptococcal pharyngitis.
Indeed, internists' major reason for not performing testing
was not being familiar with the test. Internists were signif-
icantly more likely to be unfamiliar with the test or to
report that it was not available. Pediatricians may also per-
form rapid influenza testing in order to rule out sepsis in
young children, based on the test's high specificity [17].
Although several decision analyses [18,19] have suggested
that rapid testing is not cost-effective due to the low sensi-
tivity of the test, particularly in adults [3], no pediatricians
and fewer than 5% of internists cited low sensitivity as a
reason for not testing.
Both specialties had similar beliefs about the efficacy of
antiviral therapy and prescribed equally, but pediatricians
preferred amantadine over oseltamivir. This preference
may be influenced by the American Academy of Pediatrics
Red Book, which states that the use of neuraminidase
inhibitors "in the treatment of children requires further
evaluation [20]," or it may reflect lower rates of amanta-
dine side effects in children [21] or less detailing of osel-
tamivir to pediatricians. Because this study was conducted
before the discovery of widespread amantadine resistance,
it is unknown whether pediatricians have since decreased
antiviral prescribing or simply converted to prescribing
oseltamivir. Most pediatricians restricted their prescribing
to high risk patients, while internists prescribed equally to
high-risk and average-risk patients. This may have to do
with pediatricians' belief that antiviral drugs could
Table 1: Differences in practices and beliefs by specialty
Pediatricians Internists P-value
N (%) 107 N (%) 103
Actions
Performs rapid testing 78 (73) 47 (46) < 0.0001
Prescribes antiviral drugs 63 (59) 49 (48) 0.1007
Prescribes amantadine 56 (88)* 23 (48)* < 0.0001
Prescribes oseltamivir 25 (41)* 25 (52)* 0.2282
Treats only high risk 54 (86)* 26 (53)* 0.0001
Beliefs
Shortens illness by 1 day 96 (90) 86 (84) 0.1847
Prevents complications 29 (27) 30 (29) 0.7443
Prevents hospitalization 53 (50) 39 (38) 0.0884
Decrease mortality 41 (38) 23 (22) 0.0119
None of the above 3 (3) 6 (6) 0.2798
*Denominator is total number of physicians in that specialty who 
prescribe antivirals.
Reasons for not testing by specialty Figure 1
Reasons for not testing by specialty.
0 1 02 03 04 05 06 0
Other
Uncomfortable for patients
Not specific enough
Not sensitive enough
Too expensive
Not available
Unfamiliar with test
Percent of respondents
Pediatrics
Internal Medicine
*
†
‡
*p=0.009
†p=0.013
‡p=0.0005BMC Pediatrics 2008, 8:15 http://www.biomedcentral.com/1471-2431/8/15
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decrease mortality, or hesitancy on the part of pediatri-
cians to trade off a reduction in symptoms versus poten-
tial side effects in low risk patients. In light of the recent
reports of pediatric deaths in Japanese children treated
with oseltamivir, such prudence may be warranted [22].
Our finding that 38% of pediatricians believe that antivi-
ral drugs improve mortality is particularly interesting
because there are no published antiviral studies that
include high-risk children, and no antiviral study has ever
been powered to detect a difference in mortality. On a
similar note, more pediatricians than internists believed
that antivirals could prevent hospitalization, despite the
fact that this has only been demonstrated in adults [23].
Among those who did not prescribe antiviral therapy,
both pediatricians and internists reported similar reasons
for not prescribing, specifically that patients do not
present soon enough. Although more than two-thirds of
pediatricians and internists felt this to be true, a subse-
quent study of children with influenza-like illness found
that 25% of outpatients and 42% of emergency depart-
ment patients with true influenza present within 2 days,
but that clinicians often miss the diagnosis [24]. Interest-
Reasons for not prescribing by specialty Figure 2
Reasons for not prescribing by specialty.
0 1 02 03 04 05 06 07 0
Other
Don't want to induce resistance
Drugs are unavailable in area
Drugs have too many side effects
Unfamiliar with these drugs
Drugs are not very effective
Drugs are too expensive
Influenza is self-limited
Unsure of diagnosis
Patients present too late
Percent of respondents
Pediatrics
Internal Medicine
Table 2: Multivariate analysis for physician actions
Outcome Variable* Odds ratio 95% Confidence interval
Prescribes antiviral therapy
Location (MA vs. TX) 0.26 0.13 to 0.52
Specialty (internists vs. pediatricians) 0.82 0.43 to 1.55
Believes decreases mortality 1.6 1.4 to 5.7
Low patient volume ( < 50 patients/week) 0.42 0.26 to 0.8
Prescribes amantadine
Specialty (internists vs. pediatricians) 0.18 0.06 to 0.49
Believes decreases mortality 3.37 1.13 to 9.96
Performs rapid testing
Specialty (internists vs. pediatricians) 0.30 0.17 to 0.55
Treats only high risk patients
Specialty (internists vs. pediatricians) 0.19 0.07 to 0.54
Believes decreases mortality 2.94 1.03 to 8.36
*All models include location, specialty, patient volume, physician beliefs, and performance of rapid testing. Only variables with significance of p < 
0.05 are shown, except for specialty.BMC Pediatrics 2008, 8:15 http://www.biomedcentral.com/1471-2431/8/15
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ingly, no physician cited antiviral resistance as a reason for
not prescribing antiviral therapy. At the time of the study,
antiviral resistance was rare and the clinical significance
unknown. Since then, however, amantadine resistance
has become widespread [25] and resistance to oseltamivir
has been growing [26].
Interim guidelines issued by the CDC for 2006 make
almost no distinction between the treatment of children
and adults. The guidelines stress treatment with oseltami-
vir due to high levels of amantadine resistance, with prior-
ity given to high-risk individuals where local supplies are
limited. Presumably, where supplies are sufficient, treat-
ment may extend to lower risk patients. However, no
guidance is offered on how to determine who is infected,
nor what factors to consider in deciding about treatment.
Moreover, the guidelines offer no advice on overcoming
the biggest obstacle to antiviral prescribing, namely, get-
ting patients to the doctor within the 48-hour window
during which antivirals are effective. Based on the results
of our survey, adherence to the guidelines will require
more of a change in practice by pediatricians, who gener-
ally prefer amantadine to oseltamivir. In light of the large,
unrecognized burden of influenza in children [24], spe-
cific recommendations about rapid testing would also be
welcome. Given the wide variation in practice demon-
strated in this survey, more detailed, evidence-based
guidelines, with attention to the differing concerns of
pediatricians and internists, would be welcome.
Our study has several limitations. Respondents, limited to
two academic medical centers, may not be representative
of the nation as a whole. Moreover, the anonymous
nature of the survey did not allow us to compare the
demographics of responders and non-responders. Never-
theless, the observed differences were quite striking and
not likely to have occurred by chance. Also, our survey was
conducted before the emergence of widespread amanta-
dine resistance. Consequently, prescribing practices may
have changed, though beliefs and testing practices proba-
bly have not. Given that adults and children seem to ben-
efit equally from influenza treatment [6], more detailed
guidelines are needed to ensure a standardized approach
to all patients.
Conclusion
Despite that fact that adults and children appear to benefit
equally from influenza diagnosis and treatment, pediatri-
cians appear to differ from internists in their approach to
influenza. Specifically, pediatricians are more likely to
employ rapid testing, to limit treatment to high risk
patients, to treat with amantadine and to believe that anti-
viral therapy can reduce mortality. In light of these prac-
tice differences, age-specific evidence-based
recommendations regarding rapid diagnostic testing and
antiviral therapy for influenza are warranted.
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